Journal Article

Endothelial dysfunction biomarkers in sickle cell disease: is there a role for ADMA and PAI-1?

Mendes, Fernanda Santos, de Oliveira Marina Mendes, Pinheiro Melina de Barros, Martins, Suellen Rodrigues, Alpoim Patrícia Nessralla, Toledo Sílvia Letícia de Oliveira, Ferreira Leticia Gonçalves Resende, da Silva Aislander Junio, Carvalho Maria das Graças, Rios Danyelle Romana Alves, Dusse Luci Maria Sant’Ana

2022

Overview

Within the spectrum of sickle cell disease (SCD) are sickle cell anemia (SCA), presence of hemoglobin SS (HbSS), hemoglobin SC disease (HbSC), and sickle cell β-thalassemia (Sβ-thal). Asymmetric dimethylarginine (ADMA) competitively inhibits the binding of arginine to NOS, reducing NO production. In patients with HbSS, increased levels of ADMA have been reported, as well as changes in many hemostatic biomarkers, including the plasminogen activator inhibitor type 1 (PAI-1). We hypothesized that high levels of ADMA and PAI-1 may be associated with more severe SCD. Thus, ADMA and PAI-1 levels were determined in 78 individuals including 38 adult patients with SCD and 40 control subjects. Higher levels of ADMA were shown in HbSS and Sβ-thal patients compared to controls. Concerning PAI-1, all patients showed high levels of PAI-1 compared to controls. As a role of NO in the pathogenesis of SCD has already been established, we concluded that high levels of ADMA should compromise, at least in part, NO synthesis, resulting in endothelial dysfunction. Elevated plasma levels of PAI-1 in all patients may indicate not only endothelial dysfunction but also a hypofibrinolytic state favoring thrombotic complications. Finally, high levels of ADMA and PAI-1 may be associated with more severe SCD.

• Publisher: Springer Nature B.V
• Subject: Biomarkers / Hemoglobin / Sickle cell disease